NCCN Guidelines® Insights - B-Cell Lymphomas, Version 5.2021
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for B-Cell Lymphomas
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for B-Cell Lymphomas
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Andrew D. Zelenetz, MD, PhD, Panel Chair, has disclosed receiving consulting fees from AbbVie, Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Genentech, Inc., Janssen Pharmaceutica Products, LP, MorphoSys AG, Novartis Pharmaceuticals Corporation, and Adaptive Biotech; serving as a scientific advisor for BeiGene and Bristol-Myers Squibb/Celgene/Juno; and receiving grant/research support from BeiGene, MEI Pharma Inc., and Roche Laboratories, Inc.
Leo I. Gordon, MD, Panel Vice Chair, has disclosed no relevant financial relationships.
Julie E. Chang, MD, Panel Member, has disclosed no relevant financial relationships.
Beth Christian, MD, Panel Member, has disclosed receiving grant/research support from Acerta Pharma, Celgene Corporation, Genentech, Inc., Genentech, Inc., Immunomedics, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Triphase, Seattle Genetics, Inc., and Teva Pharmaceutical Industries Ltd; receiving consulting fees from AstraZeneca Pharmaceuticals LP, Genentech, Inc., MorphoSys AG, Verastem Oncology, and Seattle Genetics, Inc.
Boyu Hu, MD, Panel Member, has disclosed receiving grant/research support from Celgene Corporation, Genentech, Inc., and CRISPR Therapeutics; and consulting fees from TG Therapeutics.
Megan Lim, MD, PhD, Panel Member, has disclosed receiving consulting fees from EUSA and Thermofisher, Inc.; and honoraria from Seattle Genetics, Inc.
Stephen D. Smith, MD, Panel Member, has disclosed receiving grant/research support from Acerta Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, BeiGene, Genentech, Inc., Incyte Corporation, Merck & Co., Inc., Denovo Biopharma, Pharmacyclics, and Portola Pharmaceuticals, Inc.; receiving consulting fees from AstraZeneca Pharmaceuticals LP, Genentech, Inc., Karyopharm Therapeutics, Kite Pharma, and Millennium Pharmaceuticals, Inc.; and serving as a scientific advisor for BeiGene and ADC Therapeutics. Their spouse receives grant/research support from Bristol-Myers Squibb, Ayala, and Ignyta; and consulting fees from Bristol-Myers Squibb and Ayala.
Mary A. Dwyer, MS, CGC, Director, Guidelines Operations, NCCN, has disclosed that she has no relevant financial relationships.
Hema Sundar, PhD, Manager, Global Clinical Content, NCCN, has disclosed no relevant financial relationships.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-21-014-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 10, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation